Key Highlights

  • Innventure (NASDAQ:INV) dropped 29.01% to around USD 0.1534 during trading on November 5, 2026, according to published market data, several days after a Strategic Review Committee was named.
  • The Board established the committee on November 2, 2026, pointing to short-term cash needs at the parent company, with no timeline set and no decisions reached.
  • An at-the-market program for up to USD 60 million was set up on October 6, 2026, serving as an option alongside a USD 75 million Equity purchase agreement signed in 2023.
  • Staff numbers dropped from 40 to 15 after the first quarter closed, while Payroll expense fell roughly 57% without counting severance, and results are set for November 12, 2026.

Strategic Review Committee Points to Funding Strain

On November 2, 2026, Innventure (NASDAQ:INV) disclosed that its Board had set up a Strategic Review Committee made up of disinterested directors, which will examine a range of Capital Options with the help of advisers who have not been named. The company flagged short-run Liquidity demands at the parent, and it noted that most consolidated cash is held by Accelsius. No schedule was fixed, and nothing has been decided yet. The stock slid 29.01% on November 5, 2026, to roughly USD 0.1534, trading 4.52 million shares for a company valued at about USD 13.31 million, based on published market data. Third-quarter results are due after the close on November 12, 2026.

Operating Units, Financing Tools and Leadership

The committee is overseeing interim funding for two operating businesses. AeroFlexx support winds down in about a month while the company pursues a sale or interim outside financing, and Refinity support ends by year-end. Accelsius retained Evercore Group as financial adviser to look into private capital raising. At the parent, an at-the-market program lets the company issue shares to the public at market rates, which brings in cash but adds Supply and dilutes current owners. Innventure stated it does not plan to use the program for Accelsius at present prices or to raise the entire USD 60 million. Dr. Bill Grieco took the chief executive Job on September 1, 2026, and Stober stepped in as CFO on October 19, 2026.

Risks and What Comes Next

Because the release omitted Debt and total cash, the November 12, 2026 results will provide the initial comprehensive snapshot since the process began. Management also stressed that Accelsius, the Subsidiary where the bulk of liquidity sits, is a distinct funding matter from the parent's. Downside factors are dilution, a price far below USD 1, possible disposals sold cheaply, and a result from the committee that remains hard to call. Board size fell from nine to seven, with six members independent; Michael Madon came on as an independent member. The 2023 standby Facility is still open as an additional way to raise funds, so dilution stays on the table. Stocks at this level, both in price and in share count, may jump on a few trades, bid-ask gaps can widen and quoted moves may reverse, so nothing here suggests the drop or a rebound will carry on.

Where Things Stand

The selloff in Innventure (NASDAQ:INV) seems driven by funding strain disclosed by management, not by operations. Taken together, the review committee, parent-level cash concerns and a share sale program raise the odds of dilution and forced disposals. Expense reductions are meaningful, but the outcome remains open. The next signposts are the November 12, 2026 results and any news on funding or a sale.